Heart transplant patients get new hope against skin cancer
NCT ID NCT00799188
Summary
This study tested whether switching heart transplant patients from standard anti-rejection drugs to a medication called everolimus could help prevent new skin cancers. It involved 175 patients who had already developed skin cancer after their transplant. Researchers compared how many new skin cancers developed over two years in patients taking everolimus versus those continuing on standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HOSPICES CIVILS de LYON
Lyon, France
Conditions
Explore the condition pages connected to this study.